Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography

Fei Gao*, Zhi Jian Wang, Xiao Teng Ma, Hua Shen, Li Xia Yang and Yu Jie Zhou*

Abstract

Background: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been demonstrated to produce significantly greater reduction in LDL cholesterol levels and cardiovascular events than standard statin therapy. However, evidence on the impact of PCSK9 inhibitors on coronary plaque composition and morphology is limited.

Methods: In this open-label randomized study, eligible patients with intermediate coronary lesions and elevated LDL cholesterol values were randomized to either alirocumab 75 mg Q2W plus statin (atorvastatin 20 mg/day or rosuvastatin 10 mg/day) therapy or standard care. Optical coherence tomography (OCT) assessments for target lesions were obtained at baseline and at 36 weeks of follow-up.

Results: LDL cholesterol levels were significantly decreased in both the alirocumab and standard care arms, whereas the absolute reduction in LDL cholesterol was significantly greater in patients treated with alirocumab (1.72 ± 0.51 vs. 0.96 ± 0.59, \( P < 0.0001 \)). Compared with standard care, the addition of alirocumab to statins was associated with significantly greater increases in minimum fibrous cap thickness (18.0 [10.8–29.2] μm vs 13.2 [7.4–18.6] μm; \( P = 0.029 \)), greater increases in minimum lumen area (0.20[0.10–0.33] mm² vs 0.13 [0.12–0.24] mm²; \( P = 0.006 \)) and a greater diminution in maximum lipid arc (15.1 [7.8–24.5] vs. 8.4 [2.0–10.5]; \( P = 0.008 \)).

Conclusions: The addition of alirocumab to statins can not only provide additional LDL cholesterol lowering effects but also have a potential role in promoting a more stable plaque phenotype.

Trial registration: ClinicalTrials.gov Identifier: NCT04851769. Registered 2 Mar 2019.

Keywords: Coronary artery disease, PCSK9 inhibitors, Statins, Coronary plaque, Optical coherence tomography

Introduction

Low-density lipoprotein (LDL) cholesterol lowering therapy with statins is the cornerstone for effective treatment of coronary artery disease [1, 2]. However, a substantial proportion of patients cannot achieve target LDL cholesterol levels or tolerate effective doses of statin therapy [3, 4]. In fact, markedly increased residual cardiac risks are observed in this population [1]. Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors can reduce intrahepatic degradation of LDL receptors, which leads to increased hepatic expression of LDL receptors and reduced LDL cholesterol levels [4, 5]. Evidence shows that the addition of PCSK9 inhibitors is associated with significantly greater reductions in LDL cholesterol levels and adverse cardiovascular events compared to statins [5–7]. Therefore, current guidelines recommend the use of PCSK9 inhibitors for patients at high cardiovascular risk who cannot reach target LDL cholesterol levels despite maximally tolerated statins [1, 2].

Recently, a series of intravascular ultrasound (IVUS) studies demonstrated that PCSK9 inhibitors in addition
to statins achieved significantly greater atheroma volume regression than statin monotherapy [8–11]. However, due to the limited spatial resolution, IVUS is unable to evaluate the effects of PCSK9 inhibitors on fibrous cap thickness (FCT), which has been confirmed as an important indicator of plaque vulnerability [12, 13]. Although it has been well established that LDL cholesterol lowering therapy with statins has favorable effects on reducing coronary atheroma burden and increasing fibrous cap thickness [14, 15], it remains unclear whether the addition of PCSK9 inhibitors could further improve FCT. Optical coherence tomography (OCT) is currently the gold standard for evaluating the small changes in FCT [16, 17]. Therefore, the aim of this study was to evaluate the effects of PCSK9 inhibitors on fibrous cap thickness by OCT imaging in patients with intermediate coronary lesions.

Methods
The study is an open-label, single-center, randomized study involving patients with intermediate coronary lesions (50–70% diameter stenosis). From March 2019 to Jan 2020, all consecutive patients who received coronary angiogram and OCT imaging in An Zhen Hospital (Beijing, China), which is a teaching hospital in which over 15,000 percutaneous coronary intervention procedures are performed each year, were evaluated. Eligible patients included those who were (I) 18–80 years of age, (II) diagnosed with stable coronary artery disease or acute coronary syndrome (ACS) on admission, (III) planned to have clinically indicated coronary angiography and identified with at least one intermediate lesion (50–70% diameter stenosis) on de novo coronary arteries, (IV) identified with elevated LDL cholesterol values (LDL cholesterol ≥1.81 mmol/L [≥70 mg/dL] for patients with ACS, or ≥2.59 mmol/L [≥100 mg/dL] for non-ACS patients) despite taking rosuvastatin 10 mg/day or atorvastatin 20 mg/day for 2–4 weeks or with maximally tolerated statin therapy, and (V) able to provide written, informed consent. The study inclusion and exclusion criteria are listed in Table 1.

The study included a 36-week open-label treatment period (including posttreatment OCT imaging), initiating within 4 weeks of baseline coronary angiogram (Fig. 1). During the open-label treatment period, patients were randomized 1:1 to either the alirocumab arm or the standard care arm. Patients in the alirocumab arm received alirocumab 75 mg Q2W on top of standard statin therapy (atorvastatin 20 mg/day or rosuvastatin 10 mg/day). The last dose of alirocumab was given at week 34. Patients in the standard care arm continued to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day. Statin dose escalation or the addition of other concomitant nonstatin lipid-lowering therapies could be considered by the physicians responsible for achieving the target LDL cholesterol levels. Antithrombotic therapy and other concomitant medications were exclusively decided by their responsible physicians. Follow-up coronary angiograms and OCT imaging analyses of the same vessels were carried out at the end of the treatment period in both arms (at week 36 ± 2 weeks). Regular medical examinations and laboratory tests were conducted at 4, 12 and 36 weeks. All enrolled patients were monitored and evaluated for medical adherence to lipid lowering therapy, safety and any other adverse events during the study period.

### Table 1 Inclusion and Exclusion criteria

| Inclusion criteria | Exclusion criteria |
|-------------------|-------------------|
| 18–80 years of age | Known hypersensitivity or contraindications to alirocumab and/or statin therapy |
| Diagnosed as stable coronary artery disease or acute coronary syndrome | Received balloon angioplasty or stent implantation for target lesion |
| Received OCT imaging measurement | Unable to conduct OCT imaging analysis |
| LDL cholesterol values ≥1.81 mmol/L for patients with ACS or ≥2.59 mmol/L for non-ACS patients despite statin therapy | Prior usage of PCSK9 inhibitors |
| At least one intermediate lesion (50–70% diameter stenosis) in de novo coronary arteries | Severe renal dysfunction (creatinine clearance < 30 mL/min) |
| Provided written informed consent | Severe hepatic dysfunction |
|                       | Baseline triglyceride > 400 mg/dl |
|                       | History of hemorrhagic stroke |
|                       | Pregnant or breast-feeding women |
|                       | Life expectancy < 1 year |
|                       | Inappropriate for the study for any reason based on the investigators’ judgement |

LDL Low-density lipoprotein, PCSK9 proprotein convertase subtilisin kexin type 9, OCT optical coherence tomography, ACS acute coronary syndrome
cholesterol, and triglycerides were measured by the central laboratory. LDL cholesterol was calculated according to the Friedewald formula [18]. The study was approved by the local medical ethics committee.

**Optical coherence tomography**

OCT images were obtained at baseline and at the 36 ± 2-week follow-up. Optical coherence tomography imaging systems (Optis or Ilumien Imaging System™, Abbott Vascular, USA) were used. Testing on contrast injection was required to ensure a complete wash-out of the vessel. The entire length of the target lesions (including 5 mm proximal and distal segments) was evaluated. All imaging analyses were performed by independent investigators who were blinded to the study protocol. Target lesions between baseline and follow-up OCT were matched and compared based on the distance from the landmarks (e.g., calcifications and branches). Calibration was required before image analysis. Values of minimum lumen area, minimum FCT, and maximum lipid arc were measured. The target plaque was characterized using previously established criteria [19].

**Study endpoints**

The primary endpoint of the study was the OCT derived absolute changes in minimum fibrous cap thickness between baseline and follow-up. Secondary endpoints included the absolute changes in minimum lumen area between baseline and follow-up, as well as the absolute changes in maximum lipid arc. Minimum fibrous cap thickness was defined as the smallest FCT in the three candidate frames selected by manual screening. The maximum lipid arc was defined as the largest lipid arc from the center of the lumen. The minimum lumen area was defined as the smallest lumen area in the target lesion calculated by automated measurements and manual corrections.

In addition, the incidence rates of major adverse cardiac events (defined as the composite outcome of death, myocardial infarction, and ischemia-driven target lesion revascularization) and treatment related adverse reactions during the follow-up period were recorded. Myocardial infarction was defined according to the fourth universal definition of myocardial infarction [20]. Ischemia-driven target lesion revascularization was defined as reintervention driven by anginal symptoms and significant angiographic stenosis (> 70% diameter stenosis).

**Statistical analysis**

Continuous variables are reported as the means ± standard deviations or median (interquartile ranges). Categorical variables are presented as counts and percentages. Continuous variables between the two groups were compared by the Mann–Whitney U test. Comparisons of continuous variables between baseline and follow-up were performed by the Wilcoxon signed rank test. Comparisons of categorical variables were performed by the Fisher’s exact test. A two-tailed test $P$ value < 0.05 was considered as statistically significant. The SPSS Statistics 25.0 package was used.

**Results**

A total of 61 eligible patients (31 patients in the standard care arm and 30 patients in the alirocumab arm) with complete clinical and OCT imaging follow-up were analyzed (Fig. 1). Nearly half of the patients (15/31) in the standard care arm received ezetimibe and statin combination therapy. The baseline and procedural characteristics of the two groups are listed in Table 2. Of note,
patients were predominantly male and had a high percentage of guideline recommended medical therapies in both groups. All the participants were prescribed antiplatelet therapy, and approximately 90% of them were treated with beta blockers.

Biochemical measures throughout the study are summarized in Table 3. At baseline, no significant differences were observed between the standard care arm and the alirocumab arm. At week 36, LDL cholesterol levels were significantly decreased in both groups compared with baseline, from 3.18 mmol/L to 2.22 mmol/L (P < 0.0001) in the standard care arm and from 3.04 mmol/L to 1.32 mmol/L in the alirocumab arm (P < 0.0001). However, the absolute changes in LDL cholesterol levels were significantly higher in patients treated with alirocumab (1.72 ± 0.51 vs. 0.96 ± 0.59, P < 0.0001). In addition, patients in alirocumab arm demonstrated favorable changes in triglyceride levels, but the differences were not significant. C-reactive protein (CRP) levels decreased changes in triglyceride levels, but the differences were not significant. C-reactive protein (CRP) levels decreased

Discussion

The results of our study indicated that the addition of alirocumab was associated with a significantly greater reduction in LDL cholesterol levels, a greater increase in FCT, and a greater diminution in maximum lipid arc, compared with standard lipid lowering therapy.

The impact of lipid lowering therapy on atheroma plaque morphology was initially established in statin trials [21]. Coronary plaque regression can be achieved when the decrease in LDL cholesterol levels exceeds 50% due to the treatment of statins [22]. However, our previous epidemiological study indicated that large numbers of patients cannot achieve sufficient LDL cholesterol reductions despite treatment with statin therapy [3]. PCSK9 inhibitors are novel pharmacologic agents, and it has been shown that the addition of PCSK9 inhibitors to statins can further reduce LDL cholesterol levels by 43 to 64% [23]. However, evidence regarding the effect of PCSK9 inhibitors on atheroma plaque stability is limited. The ODYSSEY J-IVUS trials showed that the addition of alirocumab to statins resulted in a numerical greater reduction in total atheroma volume, but it did not attain statistical significance due to the limited sample size [10]. Conversely, the GLAGOV trial reported a significant reduction in atheroma volume in patients treated with evolocumab for 76 weeks [8]. However, the GLAGOV trial showed that the addition of evolocumab did not produce differential changes in plaque composition by IVUS assessment compared to statin monotherapy. Although the addition of PCSK9 inhibitors was shown to reduce atheroma volume in these two studies, there is a gap of evidence regarding the impact of PCSK9 inhibition on other vulnerable plaque features.

Table 2 Baseline characteristics

|                      | Standard of care (N = 31) | Alirocumab (N = 30) |
|----------------------|---------------------------|---------------------|
| Age, yrs             | 61.3 ± 9.9                | 61.3 ± 8.9          |
| Male                 | 74.2 (23)                 | 66.7 (20)           |
| Diabetes             | 25.8 (8)                  | 23.3 (7)            |
| Current smoker       | 25.8 (8)                  | 20.0 (9)            |
| Hypertension         | 61.3 (19)                 | 56.7 (17)           |
| Prior MI             | 9.7 (3)                   | 13.3 (4)            |
| Prior stroke         | 3.2 (1)                   | 10.0 (3)            |
| ACS                  | 41.9 (13)                 | 36.7 (11)           |
| Antiplatelet         | 100 (31)                  | 100 (30)            |
| Beta-blocker         | 90.3 (28)                 | 93.3 (28)           |
| ACEI/ARB             | 64.5 (20)                 | 60.0 (18)           |
| Chronic statin       | 32.3 (10)                 | 26.7 (8)            |
| before enrollment    |                           |                     |
| Imaged artery        |                           |                     |
| Left anterior descending | 41.9 (13)           | 43.3 (13)           |
| Left circumflex      | 22.6 (7)                  | 26.7 (8)            |
| Right coronary       | 32.2 (10)                 | 30.0 (9)            |
| Others               | 3.2 (1)                   | 0                   |

ACS acute coronary syndrome, MI myocardial infarction, ACEI/ARB angiotensin-converting enzyme inhibitors/angiotensin receptor blockers

No death or myocardial infarction event was recorded in either the alirocumab or standard care arm (Table 5). However, 1 patient suffered from ischemia driven target lesion revascularization in the standard care arm, but not in the alirocumab arm. The incidence of treatment-related adverse reactions was similar in both groups. Nasopharyngitis (standard care: 1 patient; alirocumab: 2 patients) was the most common reaction. Two (6.7%) patients in the alirocumab group experienced local injection-site reactions. All the treatment-related adverse reactions found in this study were recorded as mild in intensity, and all the participants were tolerated following their treatment plan.
such as fibrous cap thickness. OCT imaging analysis, which has 10 times greater resolution than IVUS, is an ideal imaging modality to assess fibrous cap thickness of coronary plaque [17, 24]. A recent retrospective, observational OCT study revealed that evolocumab provided a greater increase in FCT in patients with recent acute coronary syndrome than statin monotherapy [25]. To date, there is only one randomized study evaluating the effects of PCSK9 inhibitors on plaque morphology by OCT – the ALTAIR study [26]. It enrolled 24 patients randomized to either alirocumab or statins (rosuvastatin 10 mg/d). It also showed a significantly greater increase in fibrous cap thickness in the alirocumab group than in the statin group. However, in the current study nearly half of the patients in the standard care arm received ezetimibe and statin combination therapy. It was close

| Table 3 Biochemical parameters | Standard of care (N = 31) | Alirocumab (N = 30) | P Value |
|--------------------------------|--------------------------|--------------------|---------|
| LDL cholesterol, mmol/L       |                          |                    |         |
| Baseline                       | 3.18 ± 0.97              | 3.04 ± 0.78        | –       |
| After 36 weeks treatment       | 2.22 ± 0.69              | 1.32 ± 0.39        | < 0.0001|
| Changes from baseline          | −0.96 ± 0.59             | −1.72 ± 0.51       | < 0.0001|
| HDL cholesterol, mmol/L       |                          |                    |         |
| Baseline                       | 1.30 ± 0.41              | 1.41 ± 0.61        | –       |
| After 36 weeks treatment       | 1.38 ± 0.43              | 1.48 ± 0.47        | 0.35    |
| Changes from baseline          | 0.08 ± 0.36              | 0.07 ± 0.38        | 0.74    |
| Triglycerides, mmol/L          |                          |                    |         |
| Baseline                       | 1.56 (1.19 to 2.38)      | 1.84 (1.19 to 2.56) | –       |
| After 36 weeks treatment       | 1.53 (1.09 to 2.26)      | 1.54 (1.00 to 2.09) | 0.68    |
| Changes from baseline          | −0.05 (0.64 to 1.42)     | −0.29 (−0.96 to 0.35) | 0.077  |
| CRP, mg/L                      |                          |                    |         |
| Baseline                       | 1.62 (0.90 to 3.00)      | 1.69 (0.75 to 3.37) | –       |
| After 36 weeks treatment       | 1.10 (0.89 to 2.50)      | 1.59 (0.92 to 2.61) | 0.64    |
| Changes from baseline          | 0.54 (−0.46 to 1.34)     | 0.12 (−0.74 to 1.08) | 0.50    |

CRP C-reactive protein, LDL low-density lipoprotein, HDL high-density lipoprotein

| Table 4 OCT-derived study endpoints | Standard of care (N = 31) | Alirocumab (N = 30) | P Value |
|-------------------------------------|--------------------------|--------------------|---------|
| Minimum fibrous cap thickness, um   |                          |                    |         |
| Baseline                            | 116.4 (90.1 to 136.2)    | 126.0 (87.5 to 145.5) | 0.44    |
| After 36 weeks treatment            | 124.2 (98.2 to 144.3)    | 144.0 (111.5 to 151.8) | 0.049   |
| Changes from baseline               | 13.2 (7.4 to 18.6)       | 18.0 (10.8 to 29.2)  | 0.029   |
| Maximum lipid arc, degree           |                          |                    |         |
| Baseline                            | 110.9 (90.2 to 132.4)    | 109.6 (89.8 to 130.0) | 0.53    |
| After 36 weeks treatment            | 102.2 (87.0 to 123.1)    | 93.5 (77.5 to 108.1) | 0.19    |
| Changes from baseline               | −8.4 (−2.0 to −10.5)     | −15.1 (−7.8 to −24.5) | 0.008   |
| Minimum lumen area, mm²             |                          |                    |         |
| Baseline                            | 2.47 (2.20 to 2.74)      | 2.32 (2.07 to 2.63)  | 0.22    |
| After 36 weeks treatment            | 2.60 (2.19 to 2.90)      | 2.57 (2.27 to 2.90)  | 0.77    |
| Changes from baseline               | 0.13 (0.12 to 0.24)      | 0.20 (0.10 to 0.33)  | 0.006   |
| TCFA, % (n)                         |                          |                    |         |
| Baseline                            | 25.8 (8)                 | 20.0 (6)            | 0.59    |
| After 36 weeks treatment            | 16.1 (5)                 | 3.3 (1)             | 0.09    |

TCFA thin-cap fibroatheroma
to real-world clinical practice since the recent guidelines also recommended adding an ezetimibe before initiating PCSK9 inhibitors for patients with elevated LDL cholesterol levels. The results of this study were generally consistent with previous studies and demonstrated a significantly greater increase in minimum lumen area in the alirocumab arm assessed by OCT imaging. In addition, the alirocumab arm was associated with a significantly greater increase in FCT and a greater reduction in maximum lipid arc compared with the standard care arm. The current results indicated that the addition of alirocumab can not only provide profound LDL cholesterol lowering effects but also have a potential role in improving the stability of the plaque.

Although statins have demonstrated a significant CRP lowering effect, and the degree of CRP lowering was correlated with the extent of plaque regression [27, 28] and cardiovascular event risk reduction [29], it remains controversial whether PCSK9 inhibitors have similar effects on CRP levels. A recent Mendelian randomization study found strong associations of decreased PCSK9 concentrations and increased CRP levels [30]. In this study, no incremental reductions in CRP levels were observed in patients treated with alirocumab. However, the study might be underpowered to detect the differences in CRP between the groups; thus, the differences need to be further evaluated in large studies. However, the study results suggested that the favorable effects of alirocumab on the plaque phenotype were independent of CRP changes. A previous meta-analysis also indicated that the reduction in coronary atherosclerosis observed with nonstatin lipid-lowering therapy was attributed to the degree of LDL cholesterol lowering [31]. Therefore, it seems reasonable to believe that the effects of PCSK9 on coronary plaque might be mediated by LDL cholesterol lowering Fig. 2.

**Study strength and limitations**

The current trial is the first randomized OCT imaging trial to show the superiority of alirocumab over standard lipid lowering therapy (including high-intensity statin and ezetimibe combination therapy) on plaque modification in patients with intermediate coronary lesions. However, there are several potential limitations to this study. The first major limitation is the relatively short treatment duration; therefore, the long-term effects of PCSK9 inhibitors on plaque, as well as their clinical prognosis cannot be evaluated. The second limitation is the open nature of this study. The person who conducted the OCT imaging scans and analyses were unaware of the patients’ allocation. However, the patients and treating physicians in this study were unblinded, which might influence the treatment benefits. The third limitation is that the

| Table 5 Clinical events                                      | Standard of care (N = 31) | Alirocumab (N = 30) |
|---------------------------------------------------------------|---------------------------|---------------------|
| Adverse cardiac events                                       | 0                         | 0                   |
| Cardiac death                                                | 0                         | 0                   |
| Myocardial infarction                                        | 1                         | 0                   |
| Ischemia driven target lesion revascularization              |                           |                     |
| Treatment-related adverse events                              | 1                         | 2                   |
| Nasopharyngitis                                               | 1                         | 2                   |
| Injection-site reaction                                      | 0                         | 1                   |
| Back pain                                                    | 1                         | 1                   |
| Transaminase elevation                                       |                           |                     |

![Fig. 2 Representative OCT imaging. Changes in fibrous cap thickness (white arrows) between baseline and follow-up in a patient with alirocumab](image-url)
study did not record and compare medical adherence except for lipid lowering agents. Since recent evidence showed that PCSK9 inhibitors could positively affect treatment adherence and patients’ quality of life [32, 33], it may introduce potential bias into the study. Another important limitation is that there is no compelling evidence demonstrating a direct link between the increase in OCT-derived fibrous-cap thickness and the improvement in cardiovascular prognosis. However, a series of pathological studies certified that FCT is a major determinant of vulnerable coronary plaque [12, 34]. Furthermore, it is well acknowledged that OCT-defined thin-cap fibroatheroma is correlated with vulnerable plaque characters identified by other imaging techniques [35], all of which have a strong link to future adverse clinical events [23, 36]. Therefore, to date, the increase in fibrous cap thickness has been considered a representation of coronary plaque stabilization [37–40].

Conclusions

Among patients who cannot achieve LDL cholesterol targets despite standard lipid lowering therapy, the addition of alirocumab can not only provide a greater reduction in LDL cholesterol, but also have a favorable effect on improving the vulnerability of the plaque. Further studies are needed to clarify the clinical implications of these results measured by OCT.

Abbreviations

LDL: Low-density lipoprotein; PCSK9: Proprotein convertase subtilisin kexin type 9; IVUS: Intravascular ultrasound; OCT: Optical coherence tomography; FCT: Fibrous cap thickness; ACS: Acute coronary syndrome; CRP: C-reactive protein; MI: Myocardial infarction; ACEI/ARB: Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; TCFA: Thin-cap fibroatheroma

Acknowledgements

We thank the entire study team for their participation and contributions.

Authors’ contributions

F Gao and Y J Zhou were responsible for the study design and management. H Shen were responsible for the data resources and integrity. Z J Wang and X T Ma conducted the OCT Imaging analysis. L X Yang helped with data management and statistical analysis. F Gao analyzed the data and drafted the manuscript. The authors read and approved the final manuscript.

Funding

The study was funded by the Capital’s Funds for Health Improvement and Research.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study protocol was approved by Ethics Committee of Beijing Anzhen Hospital, Capital university and all participants provided written informed consent. The study was performed in accordance with the principles of the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

None.

Received: 5 July 2021 Accepted: 23 August 2021 Published online: 12 September 2021

References

1. Amett DK, Blumenthal RS, Albert MA, Buraker AB, Goldberg ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019; 140(11):e596–646. https://doi.org/10.1161/CIR.0000000000000678.

2. Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019; 381(16):1557–67. https://doi.org/10.1056/NEJMra1806939.

3. Gao F, Zhou YJ, Hu DY, Zhao YX, Liu YY, Wang ZJ, et al. Contemporary management and attainment of cholesterol targets for patients with Dyslipidemia in China results of a Chinese Society of Cardiology National Survey – REALITY-CHINA SURVEY. Plos One. 2013;8(4):e47768. https://doi.org/10.1371/journal.pone.0047681.

4. Nicholls SJ, Nissen SE, Prati F, Windecker S, Kataoka Y, Puri R, et al. Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. Cardiovasc Diagn Ther. 2021;11(1):120–9. https://doi.org/10.21037/cdt-20-684.

5. Robinson JG, Farrier M, Kempf M, Bergeron J, Luc G, Avena M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–99. https://doi.org/10.1056/NEJMoa1501311.

6. Sabatine MS, Giugliano RP, Kech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1704224.

7. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Ritter VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107. https://doi.org/10.1056/NEJMoa1801174.

8. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of Evolocumab on coronary plaque composition. J Am Coll Cardiol. 2018;72:2012–21. https://doi.org/10.1016/j.jacc.2018.06.078.

9. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373–84. https://doi.org/10.1001/jama.2016.16651.

10. Ako J, Hiw K, Tsuita K, Hiro T, Morino Y, Kozuma K, et al. Effect of Alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome - the ODYSSEY J-I IVUS trial. Circ J. 2019;83:2025–33. https://doi.org/10.1253/circj.CJ-19-0412. 11. Gragnano F, Calabrò P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis. 2018;269:219–28. https://doi.org/10.1016/j.atherosclerosis.2018.01.012.

12. Vismani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262–75. https://doi.org/10.1161/01.ATV.20.5.1262.

13. Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Circ Qipin Cardiol. 2001;16:285–92. https://doi.org/10.1097/0001573-200109000-00006.

14. Komukai K, Kubo T, Kitabata H, Matsuo Y, Ozaki Y, Takakura S, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol. 2014;64:2207–17. https://doi.org/10.1016/j.jacc.2014.08.045.

15. Kini A, Vengrenyuk Y, Shameer K, Maehara A, Purushothaman M, Yoshimura T, et al. Intracoronary imaging, cholesterol efflux, and Transcriptomes after intensive statin treatment: the YELLOW II study. J Am Coll Cardiol. 2017; 69(6):628–40. https://doi.org/10.1016/j.jacc.2016.10.029.

16. Wei J, Wang Z, Hu Q, Chen X, Zhang X, Zhang J, et al. Contemporary management and attainment of cholesterol targets for patients with Dyslipidemia in China results of a Chinese Society of Cardiology National Survey – REALITY-CHINA SURVEY. Plos One. 2013;8(4):e47768. https://doi.org/10.1371/journal.pone.0047681.

17. Komukai K, Kubo T, Kitabata H, Matsuo Y, Ozaki Y, Takarada S, et al. Intracoronary imaging, cholesterol efflux, and Transcriptomes after intensive statin treatment: the YELLOW II study. J Am Coll Cardiol. 2017; 69(6):628–40. https://doi.org/10.1016/j.jacc.2016.10.029.

18. Wei J, Wang Z, Hu Q, Chen X, Zhang X, Zhang J, et al. Contemporary management and attainment of cholesterol targets for patients with Dyslipidemia in China results of a Chinese Society of Cardiology National Survey – REALITY-CHINA SURVEY. Plos One. 2013;8(4):e47768. https://doi.org/10.1371/journal.pone.0047681.
16. Kim Y, Johnson TW, Akasaka T, Jeong MH. The role of optical coherence tomography in the setting of acute myocardial infarction. J Cardiol. 2018;72:186–92. https://doi.org/10.1016/j.jcc.2018.03.004.

17. Kume T, Akasaka T, Kawamoto T, Okura H, Watanabe N, Toyota E, et al. Measurement of the thickness of the fibrous cap by optical coherence tomography. Am J Heart. 2006;152:735. e1–4. https://doi.org/10.1016/j.jahj.2006.06.030.

18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.

19. Tarreney GJ, Reger E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HC, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the international working Group for Intravascular Optical Coherence Tomography Standardiza- tion and validation. J Am Coll Cardiol. 2012;59:1058–72. https://doi.org/10.1016/j.jcc.2011.09.079.

20. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Executive group on behalf of the joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)World heart federation (WHF) task force for the universal definition of myocardial infarction. J Am Coll Cardiol. 2012;59:1058–72. https://doi.org/10.1016/j.jcc.2011.09.079.

21. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078–87. https://doi.org/10.1056/NEJMoa1110874.

22. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–80. https://doi.org/10.1001/jama.291.10.1071.

23. Del Pinto R, Grassi D, Properzi G, Desideri G, Ferri C. Low density lipoprotein (LDL) cholesterol as a causal role for atherosclerotic disease: potential role of PCSK9 inhibitors. High Blood Press Cardiovasc Prev. 2019;26:199–207. https://doi.org/10.1007/s12979-019-00323-7.

24. Johnson TW, Ribber L, di Mario C, Bourantas C, Jia H, Mattesini A, et al. Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2019;40(3):2566–84. https://doi.org/10.1093/eurheartj/ehz332.

25. Yano H, Horioka S, Ishimitsu T. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J Cardiol. 2020;75(3):289–95. https://doi.org/10.1016/j.jcc.2019.08.002.

26. Sugizaki Y, Otake H, Kawamori H, Toba T, Nagano Y, Tsukiyama Y, et al. Addition Alirocumab to Rosuvastatin helps reduce the vulnerability of thin-cap fibrous cap plaques in patients with acute coronary syndrome: a real-world observational study. J Cardiol. 2018;72:289–96. https://doi.org/10.1016/j.jcc.2018.04.006.

27. Gao et al. Lipids in Health and Disease (2021) 20:106

28. Schmidt AF, Hunt NB, Gordinlio-Maravón M, Chaoen P, Drenos F, et al. Cholesterin ester transfer protein as a drug target for cardiovascular disease. medRxiv. 2020. https://doi.org/10.1101/2020.09.07.20189571.

29. Masson W, Lobo M, Siniaiski D, Molinero G, Masson G, Huerín M, et al. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression. Lipids Health Dis. 2020;19(1):111. https://doi.org/10.1186/s12944-020-01297-5.

30. Cesar A, Gragnano F, Firmiani F, Moscarella E, Diana V, Pariggiano I, et al. Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. Eur J Prev Cardiol. 2020;27(5):556–8. https://doi.org/10.1177/2047487319839179.